التفاصيل البيبلوغرافية
| العنوان: |
Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in KRAS- and BRAF-mutant cancer cells. |
| المؤلفون: |
Zhang, Haibo, Read, Abigail, Cataisson, Christophe, Yang, Howard H., Lee, Wei-Chun, Turk, Benjamin E., Yuspa, Stuart H., Luo, Ji |
| المصدر: |
Science Signaling; 5/14/2024, Vol. 17 Issue 836, p1-16, 16p |
| مصطلحات موضوعية: |
PHOSPHOPROTEIN phosphatases, MITOGEN-activated protein kinases, CANCER cells, RAS oncogenes, PROTEIN kinases, BRAF genes, CELL cycle |
| مستخلص: |
The Ras–mitogen-activated protein kinase (MAPK) pathway is a major target for cancer treatment. To better understand the genetic pathways that modulate cancer cell sensitivity to MAPK pathway inhibitors, we performed a CRISPR knockout screen with MAPK pathway inhibitors on a colorectal cancer (CRC) cell line carrying mutant KRAS. Genetic deletion of the catalytic subunit of protein phosphatase 6 (PP6), encoded by PPP6C, rendered KRAS- and BRAF-mutant CRC and BRAF-mutant melanoma cells more resistant to these inhibitors. In the absence of MAPK pathway inhibition, PPP6C deletion in CRC cells decreased cell proliferation in two-dimensional (2D) adherent cultures but accelerated the growth of tumor spheroids in 3D culture and tumor xenografts in vivo. PPP6C deletion enhanced the activation of nuclear factor κB (NF-κB) signaling in CRC and melanoma cells and circumvented the cell cycle arrest and decreased cyclin D1 abundance induced by MAPK pathway blockade in CRC cells. Inhibiting NF-κB activity by genetic and pharmacological means restored the sensitivity of PPP6C-deficient cells to MAPK pathway inhibition in CRC and melanoma cells in vitro and in CRC cells in vivo. Furthermore, a R264 point mutation in PPP6C conferred loss of function in CRC cells, phenocopying the enhanced NF-κB activation and resistance to MAPK pathway inhibition observed for PPP6C deletion. These findings demonstrate that PP6 constrains the growth of KRAS- and BRAF-mutant cancer cells, implicates the PP6–NF-κB axis as a modulator of MAPK pathway output, and presents a rationale for cotargeting the NF-κB pathway in PPP6C-mutant cancer cells. Editor's summary: Inhibitors of the Ras-MAPK pathway are used to treat cancers carrying RAS and BRAF mutations. Zhang et al. performed a CRISPR-based screen to find modulators of the MAPK pathway and found that protein phosphatase 6 (PP6) increased sensitivity to MAPK pathway inhibitors. Deletion of the catalytic subunit of PP6 promoted the growth of KRAS- and BRAF-mutant cells in spheroid cultures and in mice in an NF-κB–dependent manner and increased their resistance to MAPK pathway inhibitors. These findings indicate that PP6 contributes to MAPK sensitivity in KRAS- and BRAF-mutant cells and suggest that the NF-κB pathway may be cotargeted in PP6C-mutant cells. —Amy E. Baek [ABSTRACT FROM AUTHOR] |
|
Copyright of Science Signaling is the property of American Association for the Advancement of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
